CA2466641A1 - Lyophilized monoclonal antibody compositions - Google Patents

Lyophilized monoclonal antibody compositions Download PDF

Info

Publication number
CA2466641A1
CA2466641A1 CA002466641A CA2466641A CA2466641A1 CA 2466641 A1 CA2466641 A1 CA 2466641A1 CA 002466641 A CA002466641 A CA 002466641A CA 2466641 A CA2466641 A CA 2466641A CA 2466641 A1 CA2466641 A1 CA 2466641A1
Authority
CA
Canada
Prior art keywords
composition
monoclonal antibody
lyophilized
disaccharide
hes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002466641A
Other languages
English (en)
French (fr)
Inventor
Tracy Chen
Glen Tolman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2466641A1 publication Critical patent/CA2466641A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002466641A 2001-11-09 2002-10-18 Lyophilized monoclonal antibody compositions Abandoned CA2466641A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34206301P 2001-11-09 2001-11-09
US60/342,063 2001-11-09
PCT/US2002/033272 WO2003041637A2 (en) 2001-11-09 2002-10-18 Lyophilized monoclonal antibody compositions

Publications (1)

Publication Number Publication Date
CA2466641A1 true CA2466641A1 (en) 2003-05-22

Family

ID=23340162

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002466641A Abandoned CA2466641A1 (en) 2001-11-09 2002-10-18 Lyophilized monoclonal antibody compositions

Country Status (7)

Country Link
EP (1) EP1455822A4 (es)
JP (1) JP2005508992A (es)
AR (1) AR037304A1 (es)
CA (1) CA2466641A1 (es)
MX (1) MXPA04004459A (es)
TW (1) TW200303213A (es)
WO (1) WO2003041637A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
CA2744510A1 (en) * 2008-12-09 2010-06-17 F.Hoffmann-La Roche Ag Method for obtaining an excipient-free antibody solution
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
LT3111954T (lt) 2010-11-05 2019-07-10 Novartis Ag Ankilozuojančio spondilito gydymo būdai, naudojant anti-il-17 antikūnus
BR112020004902A2 (pt) 2017-09-15 2020-09-15 Amgen Inc. processo para formulação farmacêutica liofilizada de uma proteína terapêutica

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229810B1 (en) * 1985-07-09 1991-10-16 Quadrant Bioresources Limited Protection of proteins and the like
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
WO1993000807A1 (en) * 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
WO1993014191A1 (en) * 1992-01-21 1993-07-22 Cryopharm Corporation Method of freezing cells and cell-like materials
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
IL122482A (en) * 1995-06-07 1999-10-28 Quadrant Holdings Cambridge Methods for stably incorporating substances within dry foamed glass matrices and compositions obtained thereby
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
EP2325205A3 (en) * 2000-12-28 2011-10-12 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them

Also Published As

Publication number Publication date
AR037304A1 (es) 2004-11-03
TW200303213A (en) 2003-09-01
EP1455822A2 (en) 2004-09-15
EP1455822A4 (en) 2004-12-29
MXPA04004459A (es) 2005-05-16
WO2003041637A2 (en) 2003-05-22
WO2003041637A3 (en) 2004-01-22
JP2005508992A (ja) 2005-04-07

Similar Documents

Publication Publication Date Title
AU2013255413C1 (en) Pharmaceutical formulations of TNF-alpha antibodies
US10786567B2 (en) Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine
AU772940B2 (en) Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies
KR101273568B1 (ko) 약제학적 항-종양 괴사 인자-α 항체 제제
ES2897500T3 (es) Formulaciones de anticuerpos T1h
CA2037884C (en) Stabilized gonadotropin containing preparations
US11241498B2 (en) Room temperature stable lyophilized protein
US20090068196A1 (en) Pharmaceutical formulation of an antibody against IL13Ralpha1
US20030092607A1 (en) High-concentration protein formulations and method of manufacture
CA2466641A1 (en) Lyophilized monoclonal antibody compositions
WO2018124948A1 (ru) ВОДНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО МОНОКЛОНАЛЬНОГО АНТИТЕЛА К ФНОα
RU2665966C2 (ru) Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα
AU2002337895A1 (en) Lyophilized monoclonal antibody compositions
CN115812080A (zh) 含有抗ctla-4抗体的稳定调配物
RU2764521C2 (ru) Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОа
KR20230165828A (ko) 항-MUC16 x 항-CD3 이중특이적 항체를 함유하는 안정화된 제형
KR20230146515A (ko) 개선된 동결건조 제형
CN115998690A (zh) 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
BRPI9715268B1 (pt) preparações farmacêuticas liofilizadas estáveis de anticorpos monoclonais ou policlonais, bem como processo para sua produção
MX2008008021A (es) Formulaciones de proteina con viscosidad reductiva y sus usos

Legal Events

Date Code Title Description
FZDE Dead